Opus Genetics (IRD) Competitors $1.72 +0.08 (+4.88%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$1.74 +0.02 (+1.16%) As of 09/25/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IRD vs. DSGN, LRMR, MBX, ALT, TECX, TVRD, FDMT, CTMX, ENGN, and AMRNShould you be buying Opus Genetics stock or one of its competitors? The main competitors of Opus Genetics include Design Therapeutics (DSGN), Larimar Therapeutics (LRMR), MBX Biosciences (MBX), Altimmune (ALT), Tectonic Therapeutic (TECX), Tvardi Therapeutics (TVRD), 4D Molecular Therapeutics (FDMT), CytomX Therapeutics (CTMX), enGene (ENGN), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry. Opus Genetics vs. Its Competitors Design Therapeutics Larimar Therapeutics MBX Biosciences Altimmune Tectonic Therapeutic Tvardi Therapeutics 4D Molecular Therapeutics CytomX Therapeutics enGene Amarin Design Therapeutics (NASDAQ:DSGN) and Opus Genetics (NASDAQ:IRD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation. Does the media prefer DSGN or IRD? In the previous week, Design Therapeutics and Design Therapeutics both had 1 articles in the media. Design Therapeutics' average media sentiment score of 1.89 equaled Opus Genetics'average media sentiment score. Company Overall Sentiment Design Therapeutics Very Positive Opus Genetics Very Positive Which has more risk & volatility, DSGN or IRD? Design Therapeutics has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500. Do institutionals and insiders believe in DSGN or IRD? 56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 15.0% of Opus Genetics shares are held by institutional investors. 23.5% of Design Therapeutics shares are held by insiders. Comparatively, 6.6% of Opus Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts prefer DSGN or IRD? Opus Genetics has a consensus target price of $7.33, indicating a potential upside of 326.36%. Given Opus Genetics' stronger consensus rating and higher probable upside, analysts clearly believe Opus Genetics is more favorable than Design Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Design Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Opus Genetics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is DSGN or IRD more profitable? Design Therapeutics has a net margin of 0.00% compared to Opus Genetics' net margin of -377.89%. Design Therapeutics' return on equity of -27.15% beat Opus Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Design TherapeuticsN/A -27.15% -26.07% Opus Genetics -377.89%-384.33%-148.90% Which has better earnings and valuation, DSGN or IRD? Design Therapeutics has higher earnings, but lower revenue than Opus Genetics. Design Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDesign TherapeuticsN/AN/A-$49.59M-$1.12-5.46Opus Genetics$10.99M9.38-$57.53M-$1.92-0.90 SummaryDesign Therapeutics beats Opus Genetics on 8 of the 13 factors compared between the two stocks. Get Opus Genetics News Delivered to You Automatically Sign up to receive the latest news and ratings for IRD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRD vs. The Competition Export to ExcelMetricOpus GeneticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.25M$3.13B$5.75B$10.39BDividend YieldN/A2.39%5.75%4.64%P/E Ratio-0.9020.6375.7726.11Price / Sales9.38442.69544.62124.93Price / CashN/A44.6737.5461.24Price / Book8.199.6212.876.30Net Income-$57.53M-$52.73M$3.29B$271.03M7 Day Performance13.16%1.81%0.28%-0.14%1 Month Performance42.74%5.50%2.87%5.82%1 Year PerformanceN/A18.12%65.66%27.63% Opus Genetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRDOpus Genetics2.4978 of 5 stars$1.72+4.9%$7.33+326.4%N/A$98.25M$10.99M-0.9014Positive NewsDSGNDesign Therapeutics0.2563 of 5 stars$5.89+0.5%N/A+13.6%$335.44MN/A-5.2640LRMRLarimar Therapeutics2.5278 of 5 stars$4.01+1.1%$18.43+360.1%-23.3%$329.87MN/A-2.5530Positive NewsMBXMBX Biosciences2.8456 of 5 stars$9.79-9.9%$37.63+284.3%-25.2%$327.54MN/A-2.1536Trending NewsAnalyst ForecastGap DownALTAltimmune2.6512 of 5 stars$3.65+1.5%$17.40+377.4%-44.0%$322.58M$20K-3.1050Trending NewsTECXTectonic Therapeutic2.8177 of 5 stars$17.04+2.7%$80.29+371.1%-50.0%$319.57MN/A-4.23120TVRDTvardi Therapeutics2.47 of 5 stars$34.03+0.8%$64.25+88.8%N/A$319.10MN/A0.0080News CoveragePositive NewsFDMT4D Molecular Therapeutics2.7605 of 5 stars$6.73-1.0%$30.40+351.7%-25.4%$314.29M$40K-1.91120Positive NewsCTMXCytomX Therapeutics4.1936 of 5 stars$1.91-4.3%$5.75+201.8%+142.7%$314.15M$138.10M3.40170Analyst ForecastAnalyst RevisionGap DownENGNenGene2.5817 of 5 stars$6.07+1.7%$21.00+246.0%+4.0%$310.21MN/A-3.1931AMRNAmarin0.4458 of 5 stars$14.98+0.3%$12.00-19.9%+36.2%$309.73M$219.36M-4.08360 Related Companies and Tools Related Companies Design Therapeutics Alternatives Larimar Therapeutics Alternatives MBX Biosciences Alternatives Altimmune Alternatives Tectonic Therapeutic Alternatives Tvardi Therapeutics Alternatives 4D Molecular Therapeutics Alternatives CytomX Therapeutics Alternatives enGene Alternatives Amarin Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRD) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Opus Genetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Opus Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
